title: Granulocyte colony-stimulating factor-primed leukocyte transfusions in candida tropicalis fungemia in neutropenic patients.
abstract: Optimal management of fungemia in neutropenic patients is still controversial. Several reports have already stressed the poor prognosis in invasive candidiasis (80% mortality in several reports). Therefore granulocyte transfusions would appear to be useful in the management of these infections. We report the use of rhG-CSF-primed granulocyte transfusions plus amphotericin B in two neutropenic patients who developed life-threatening systemic fungal infections. This approach was successful and both patients fully recovered from the infection.
authors.affiliation: Hematology Chair, Università Cattolica S. Cuore, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Di Mario
authors.forename: S
authors.initials: S
authors.lastname: Sica
authors.forename: P
authors.initials: P
authors.lastname: Salutari
authors.forename: E
authors.initials: E
authors.lastname: Ortu La Barbera
authors.forename: R
authors.initials: R
authors.lastname: Marra
authors.forename: G
authors.initials: G
authors.lastname: Leone
mesh_terms: D000208:Acute Disease; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D016469:Fungemia / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy; D017708:Leukocyte Transfusion; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012074:Remission Induction; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000666:Amphotericin B; D008942:Mitoxantrone